Ford's World Headquarters. Photo Courtesy of Ford Motor Company.
When Alan Mulally took over as Ford's (NYSE: F ) CEO in 2006 he knew that he had a big task ahead in turning the Blue Oval around. In the first two years, between 2006 and 2008, the company lost more than $30 billion ��a ridiculous number. Yet, due to Mulally's "One Ford" vision and his executives' teamwork to cut costs and improve vehicle demand with higher-quality vehicles, Ford made a profit in 2009 ��while other automakers were claiming bankruptcy. Ford continued on that path and finds itself in better shape than it's been in a decade. Let's take a look at its recent success and assess how close Ford is to achieving its goal of bringing jobs to its operations in the U.S.
Driving sales
Looking at the top-selling vehicles in the U.S. market this year it's quickly evident why Ford is a healthy company in hiring mode. It owns four of the nation's 15 top-selling vehicles, and its F-Series has owned the No. 1 spot for 31 years. The Escape and the Fusion both have a good chance to surpass 300,000 vehicles sold in the U.S. this year ��something only the F-Series has done for Ford in the last nine years. Ford's also adding plant capacity to produce more Fusion's this fall because it's estimated to be running near or over maximum capacity.
Top Sliver Stocks To Invest In 2015: NeoStem Inc (NBS)
NeoStem, Inc., incorporated on September 18, 1980, operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�� business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�� wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing.
PCT has two cGMP, cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. The Company�� wholly-owned subsidiary, Amorcyte, LLC (Amorcyte) is developing its own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents its clinically advanced therapeutic product candidate and enrollment for its Phase II PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (AMI) patients.
Through the Company�� subsidiary, Athelos Corporation (Athelos), the Company is collaborating w! ith Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. The Company�� pre-clinical assets include its Very Small Embryonic Like (VSEL) Technology platform. The Company has basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States.
Advisors' Opinion:- [By Monica Gerson]
NeoStem (NYSE: NBS) priced an underwritten public offering of 5,000,000 shares of common stock at an offering price of $7.00 per share. NeoStem shares dipped 9.44% to $7.10 in after-hours trading.
- [By John Udovich]
Small cap ALS and stem cell stock�Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) surged 22.68%�ahead if its Monday ice bucket challenge when they will release the final results from�a phase 2a clinical trial���meaning its worth taking a closer look at the stock along with the performance of stem cell stocks or ALS stocks like Cytokinetics, Inc (NASDAQ: CYTK), Neuralstem, Inc (NYSEMKT: CUR) and NeoStem Inc (NASDAQ: NBS). However, Brainstorm Cell Therapeutics does have a history of being the subject of paid promotions and/or investor relations activities when it was trading on the OTC.
- [By John Udovich]
The results of a recent Pew Center Poll regarding attitudes towards abortion and various forms of stem cell research could be a good sign for the stem cell industry along with small cap stem cell stocks like StemCells Inc (NASDAQ: STEM), NeoStem Inc (NASDAQ: NBS), Neuralstem, Inc (NYSEMKT: CUR),�International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX). Basically, Americans think that having an abortion is a moral issue with 49% of American adults believing abortion is morally wrong, 23%�view it not as a moral issue and and 15% view it as morally acceptable. However and when Americans were asked about issues surrounding�human embryos, such as stem cell research or in vitro fertilization, as a matter of morality, their views were different.
Top 10 Quality Stocks To Watch Right Now: iShares U.S. Aerospace & Defense ETF (ITA)
iShares Dow Jones U.S. Aerospace & Defense Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Aerospace & Defense Index (the Index). The Index measures the performance of the aerospace and defense sector of the United States equity market. Aerospace companies include manufacturers, assemblers and distributors of aircraft and aircraft parts. Defense companies include producers of components and equipment for the defense industry, such as military aircraft, radar equipment and weapons.
The Fund will concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. Since all of the securities included in the Index are issued by companies in the aerospace and defense sector, the Fund will be concentrated in the aerospace and defense industry. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Mark Salzinger]
This industry's two largest ETFs��Shares Aerospace and Defense (ITA) and PowerShares Aerospace and Defense (PPA)��ained more than 50% last year.
Top 10 Quality Stocks To Watch Right Now: Armstrong World Industries Inc (AWI)
Armstrong World Industries, Inc. (AWI), incorporated on December 30, 1891, is a global producer of flooring products and ceiling systems for use in the construction and renovation of residential, commercial and institutional buildings. The Company designs, manufactures and sells flooring products (resilient and wood) and ceiling systems (mineral fiber, fiberglass and metal) globally. The Company segments includes: Building Products, Resilient Flooring and Wood Flooring. The Company�� Building Products, Resilient Flooring, Wood Flooring and Cabinets segments sell products for use in the home. Its products are used in new home construction and existing home renovation work. Its products, primarily ceilings and Resilient Flooring, are used in commercial and institutional buildings. On September 1, 2012, it sold Patriot Flooring Supply, Inc. to The Belknap White Group. Effective October 31, 2012, the Company sold of its cabinets business to American Industrial Partners.
Building Products
Building Products produces suspended mineral fiber, soft fiber and metal ceiling systems for use in commercial, institutional and residential settings. In addition, its Building Products segment sources complementary ceiling products. Its products, which are sold globally, are available in colors, performance characteristics and designs, and offer attributes, such as acoustical control, rated fire protection and aesthetic appeal. Commercial ceiling materials and accessories are sold to ceiling systems contractors and to resale distributors. Residential ceiling products are sold in North America to wholesalers and retailers, including home centers. Suspension system (grid) products manufactured by Worthington Armstrong Venture (WAVE) are sold by both the Company and WAVE.
Resilient Flooring
Resilient Flooring produces and sources a range of floor coverings for homes and commercial and institutional buildings. Manufactured products in this segment include vinyl sheet, v! inyl tile and linoleum flooring. In addition, its Resilient Flooring segment sources and sells laminate flooring products, vinyl tile products, vinyl sheet products, adhesives, and installation and maintenance materials and accessories. Resilient Flooring products are offered in a range of types, designs, and colors. It sells these products globally to wholesalers, home centers, retailers, contractors and to the manufactured homes industry.
Wood Flooring
The Company�� Wood Flooring segment produces and sources wood flooring products for use in new residential construction and renovation, with commercial applications in stores, restaurants and offices. The product offering includes pre-finished solid and engineered wood floors in various wood species, and related accessories. All of its Wood Flooring sales are in North America. Its Wood Flooring products are sold to independent wholesale flooring distributors and home centers.
The Company competes with Saint-Gobain, Chicago Metallic Corporation, Georgia-Pacific Corporation, Knauf AMF GmbH & Co. KG, Lafarge SA, Odenwald Faserplattenwerk GmbH, Rockfon A/S, USG Corporation, Amtico International, Inc., Beaulieu International Group, N.V., Boa-Franc, Inc., Congoleum Corporation, Faus, Inc., Forbo Holding AG, Gerflor Group, Interface, Inc., IVC Group, Krono Holding AG, LG Floors, Mannington Mills, Inc., Metroflor Corporation, Mullican Flooring, L.P., Mohawk Industries, Inc., Nora Systems GmbH, Pfleiderer AG, Shaw Industries, Inc., Somerset Hardwood Flooring, Tarkett AG.
Advisors' Opinion:- [By Monica Gerson]
Armstrong World Industries (NYSE: AWI) cut its Q3 forecast citing price pressures in Europe and a market shift in North America. Armstrong World shares declined 4.58% to $46.50 in the after-hours trading session.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Armstrong World Industries (NYSE: AWI ) , whose recent revenue and earnings are plotted below.
Top 10 Quality Stocks To Watch Right Now: Vocus Inc.(VOCS)
Vocus, Inc. provides cloud marketing software that enables businesses attract, engage, and retain customers in the United States, Europe, Asia, and Morocco. It offers a suite of software for social media marketing, search marketing, email marketing, and publicity. The company?s cloud marketing solutions include search marketing and news distribution solution that helps customers increase their online visibility and organic search engine rankings with press releases; and email marketing solution, which provides a method of keeping in touch with prospects and customers by using professional looking emails to send newsletters, special offers, and other useful content. Its cloud marketing solutions also comprise social media software solution that helps customers run social marketing campaigns, as well as monitor and analyze conversations across multiple social networks and other online Websites; and publicity solution, which offers media database, news monitoring, and analyt ics and publicity opportunities that help companies increase their media exposure, manage relationships with reporters, and monitor and analyze trends unfolding in the media. The company also provides professional services that consist of data migration, custom development, and training. Vocus, Inc. sells its products to the financial and insurance, technology, healthcare and pharmaceutical, and retail and consumer products industries, as well as government agencies, not-for-profit organizations, and educational institutions through its direct sales channels, indirect sales channels, and the Internet. Vocus, Inc. was founded in 1988 and is headquartered in Beltsville, Maryland.
Advisors' Opinion:- [By Seth Jayson]
Vocus (Nasdaq: VOCS ) reported earnings on April 23. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Vocus met expectations on revenues and missed estimates on earnings per share. - [By Alex Planes]
What: Shares of Vocus (NASDAQ: VOCS ) have plunged 15% today after the company's forward guidance failed to impress the Street.
So what: Vocus reported its earnings last evening, and both the $46.6 million top line and the $0.01 earnings per share result were better than Wall Street's consensus, which sought a $45.3 million revenue number and a $0.02 loss per share. However, third-quarter guidance of $46.5 million to $46.8 million on the top line is below the $47 million consensus, and a $0.03 to $0.04 EPS result is roughly in line with the $0.03 consensus. Additionally, the full fiscal year's guidance of $188 million to $189 million is roughly in line with the $188.2 million consensus.
- [By Rich Smith]
In a separate statement, the company announced a small change in management, bringing in ex-Vocus (NASDAQ: VOCS ) Chief Operating Officer William R. Wagner to become its own COO. In an SEC filing, LogMeIn noted that it will pay Wagner $400,000 in annual base salary, plus:
- [By The GeoTeam]
Our recent 2013 articles on SaaS companies Selectica (SLTC), E2open (EOPN), Responsys (MKTG), Vocus (VOCS), and ExactTarget (ET) highlighted such opportunities. The average return since the inception of our coverage currently stands at around 34% (55% at their highs).
Top 10 Quality Stocks To Watch Right Now: Franklin Covey Company (FC)
Franklin Covey Co. provides training and consulting solutions to address leadership, execution, productivity, trust, customer loyalty, sales performance, and education problems worldwide. The company also offers clients with training in management skills, relationship skills, and individual effectiveness, as well as personal-effectiveness literature and electronic educational solutions. In addition, it sells a suite of individual-effectiveness and leadership-development training products; and books, e-books, audio media, downloadable and paper-based tools, content-rich software applications for smart phones and other handheld devices, training accessories, and other related products. The company delivers its products and services through onsite presentations, facilitators, international licensees, e-learning, public workshops, custom solutions, intellectual property licenses, and media publishing methods to organizational clients, including corporations, governmental agenc ies, educational institutions, and other organizations, as well as individual clients. Franklin Covey Co. was founded in 1983 and is headquartered in Salt Lake City, Utah.
Advisors' Opinion:- [By Laura Brodbeck]
Tuesday
Earnings Expected: IHS Inc. (NYSE: IHS), Commercial Metals Company (NYSE: CMC), Franklin Covey Company (NYSE: FC), Micron Technology, Inc. (NASDAQ: MU), Apollo Group, Inc. (NASDAQ: APOL) Economic Releases Expected: French consumer confidence, German unemployment rate, Brazilian CPI, Canadian trade balanceWednesday
- [By Seth Jayson]
Franklin Covey (NYSE: FC ) reported earnings on July 9. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 1 (Q3), Franklin Covey beat expectations on revenues and beat expectations on earnings per share. - [By Laura Brodbeck]
Tuesday
Earnings Expected: A. Schulman (NASDAQ: SHLM), Acuity Brands (NYSE: AYI), Franklin Covey (NYSE: FC) and Paychex (NASDAQ: PAYX) Economic Releases Expected: US ISM manufacturing PMI, US redbook, British manufacturing PMI, German unemployment rate, French manufacturing PMI, Italian manufacturing PMI, Spanish manufacturing PMI and Reserve Bank of Australia interest rate decisionWednesday
Top 10 Quality Stocks To Watch Right Now: Insys Therapeutics Inc (INSY)
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The Company�� pharmaceuticals portfolio consists of one approved product and a number of product candidates targeting cancer-supportive care and cancer therapy. The Company�� product candidate includes Subsys, Dronabinol SG Capsule, Dronabinol RT Capsule, Dronabinol Oral Solution, Dronabinol Inhalation Device, and Dronabinol IV Solution. The Company is also developing cancer therapeutics, which is LEP-ETU, a formulation of paclitaxel, the active ingredient in the cancer drugs Taxol and Abraxane. On August 19, 2011, the Food & Drug Administration (FDA) approved its Dronabinol SG Capsule product, a generic equivalent to Marinol, for the treatment of chemotherapy induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with acquired immune deficiency syndrome (AIDS).
Subsys
The Company's Subsys is a single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue. Subsys is a transmucosal product to show pain relief when measuring the sum of pain intensity difference at five minutes in a Phase 3 breakthrough cancer pain (BTCP) clinical trial using fentanyl.
Dronabinol Product Family
The Company has an approved dronabinol product and is developing several dronabinol product candidates for the treatment of CINV and appetite stimulation in patients with AIDS, as well as other indications where dronabinol could have potential therapeutic benefits. Dronabinol, the active ingredient in Marinol, is a synthetic cannabinoid whose chemical name is delta-9-tetrahydrocannabinol (THC). Its portfolio consists of its Dronabinol SG Capsule product and Dronabinol RT Capsule product candidate, which are intended to be generic equi! valents to Marinol, in addition to three formulations, including Dronabinol Oral Solution. Dronabinol SG Capsule is a dronabinol soft gelatin capsule intended to be a generic equivalent to Marinol. Dronabinol RT Capsule is a dronabinol soft gel capsule that is stable at room temperature. Dronabinol Oral Solution is a ynthetic THC in an oral liquid formulation.
Cancer Therapeutics
In addition to its cancer-supportive care products, the Company intends to develop cancer therapeutics targeting limitations of existing commercial products. LEP-ETU, it advanced cancer therapeutic, is a NeoLipid liposomal, or microscopic membrane-like structure created from lipids, formulation that incorporates paclitaxel. LEP-ETU completed a Phase 2 clinical trial of 70 patients with metastatic breast cancer.
The Company competes with Cephalon, Inc., BioDelivery Sciences International, Inc., ProStrakan Group plc, Nycomed International Management GmbH, Archimedes Pharma Ltd., TEVA Pharmaceuticals USA, Watson Pharmaceuticals, Inc., AcelRx Pharmaceuticals, Inc., Akela Pharma Inc., Abbott Laboratories, Pharmaceutical International, Inc., Par Pharmaceutical Companies Inc., sanofi-aventis, Eisai Inc., Helsinn Group, Roche Holding AG, Par Pharmaceutical Companies Inc., GlaxoSmithKline plc, ProStrakan Group plc, Merck & Co, GW Pharmaceutical, A.P. Pharma, Inc., Aphios Corp., Roche Holding, Tesaro, Inc., Cornerstone Pharmaceutical, Inc., Bristol-Myers Squibb, Celgene Corporation, Laboratories, Amgen Inc., AstraZeneca PLC., Bayer AG, Biogen Idec Inc., Eisai Co., Ltd., F. Hoffmann- LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Onyx Pharmaceuticals Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of INSYS Therapeutics (NASDAQ: INSY) were down 15.94 percent to $38.00 after the company received subpoena from Office of Inspector General. - [By Louis Navellier]
INSYS Therapeutics (INSY) is a biotech company that focuses on developing pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. Their products include drugs that help patients deal with pain form the disease and help alleviate nausea and pain from chemotherapy. The company reported earnings this week and both profits and sales have exploded higher.
- [By Jake L'Ecuyer]
INSYS Therapeutics (NASDAQ: INSY) was also down, falling 15.14 percent to $27.73 after news broke that a doctor had fraudulently prescribed its drug Subsys.
- [By David Zeiler]
2. Insys Therapeutics Inc. (Nasdaq: INSY): Insys is a biotech seeking to capitalize on the growing interest in medical marijuana by using a generic form of THC to create drugs to treat cancer pain. INSY had its IPO May 2 with an offer price of $8 a share. The stock rose 19.75% on its first day of trading. But investors really warmed up to Insys later; it currently trades at about $37.54, a 369.25% increase over the offer price.
Top 10 Quality Stocks To Watch Right Now: Cardica Inc.(CRDC)
Cardica, Inc. engages in the development of an endoscopic microcutter product line for use by thoracic, bariatric, colorectal, and general surgeons primarily in the United States and internationally. Its microcutter product line under development includes Microcutter XPRESS 30, a multi-fire endolinear microcutter device based on the company?s proprietary ?staple-on-a-strip? technology; Microcutter XPRESS 45, a multi-fire endolinear microcutter device with a 45 millimeter staple line; Microcutter XCHANGE 30, a cartridge based microcutter device; Microcutter FLEXCHANGE 30, a cartridge based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling; and Microcutter XPRESS 60, a cutting and stapling device for the bariatric and thoracic surgery markets. The company also designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery. It offers C-Port Distal Anas tomosis Systems, such as C-Port xA Anastomosis System to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A Anastomosis System to enable automated anastomoses to be performed as part of coronary artery bypass grafting procedures; C-Port X-CHANGE System, a cartridge-based reloadable C-Port system; and PAS-Port Proximal Anastomosis System to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. In addition, the company licenses its intellectual property in the robotics field in diagnostic or therapeutic medical procedures. Cardica, Inc. sells its products through direct sales force, as well as through independent distributors and manufacturers? representatives. The company was formerly known as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. Cardica, Inc. was founded in 1997 and is headquartered in Redwood C ity, California.
Advisors' Opinion:- [By Bryan Murphy]
Neither Acorn Energy Inc. (NASDAQ:ACFN) nor Cardica, Inc. (NASDAQ:CRDC) may look all that compelling with just a passing glance. The longer one examines CRDC and ACFN, however - and really gets a grasp of their underlying stories - the more compelling each one becomes. In fact, newcomers may want to go ahead and put both budding stocks on their watchlists, if not in their portfolios.
No comments:
Post a Comment